Anika Therapeutics (ANIK) Depreciation and Depletion (2024 - 2026)

Anika Therapeutics (ANIK) has 3 years of Depreciation and Depletion data on file, last reported at $1.4 million in Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $1.4 million, up 16.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.5 million (up 12.24% YoY), and the FY2025 annual result was $5.4 million, up 8.0% from the prior year.
• Depreciation and Depletion held at $1.4 million in Q1 2026 per ANIK's latest filing, from $1.4 million in the prior quarter.
• Over five years, Depreciation and Depletion peaked at $1.4 million in Q3 2025 and troughed at $1.2 million in Q1 2024.
• A 3-year average of $1.3 million and a median of $1.3 million in 2024 frame the typical range for Depreciation and Depletion.
• On a YoY basis, Depreciation and Depletion climbed as much as 16.67% in 2025 and fell as far as 0.0% in 2025.
• A 3-year view of Depreciation and Depletion shows it stood at $1.2 million in 2024, then increased by 16.67% to $1.4 million in 2025, then changed by 0.0% to $1.4 million in 2026.
• Business Quant data shows ANIK's Depreciation and Depletion at $1.4 million in Q1 2026, $1.4 million in Q4 2025, and $1.4 million in Q3 2025.